menu
    • menu
    [{"orgOrder":0,"company":"Royer Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Royer Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Royer Biomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Royer Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HTX-034","moa":"COX-2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Remedor Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Remedor Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Remedor Biomed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Remedor Biomed \/ Undisclosed"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Karyopharm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"AUP-16","moa":"FGF2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurealis Therapeutics \/ Xbiome","highestDevelopmentStatusID":"7","companyTruncated":"Aurealis Therapeutics \/ Xbiome"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Polish Stem Cells Bank","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"POLAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Allogeneic Adsc Stem Cell","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Medical University of Warsaw \/ Polish Stem Cells Bank","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of Warsaw \/ Polish Stem Cells Bank"},{"orgOrder":0,"company":"Virchow Group","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virchow Group \/ Adocia","highestDevelopmentStatusID":"7","companyTruncated":"Virchow Group \/ Adocia"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"University of Guadalajara","sponsor":"Cell Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"MEXICO","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"University of Guadalajara","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Guadalajara \/ Cell Pharma","highestDevelopmentStatusID":"7","companyTruncated":"University of Guadalajara \/ Cell Pharma"},{"orgOrder":0,"company":"Aposcience","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"APO-2","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aposcience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aposcience \/ FGK Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Aposcience \/ FGK Clinical Research"},{"orgOrder":0,"company":"Transwell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TWB-103","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Transwell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Transwell Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transwell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Supergenics Life Science Sdn. Bhd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Supergenics Life Science Sdn. Bhd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Supergenics Life Science Sdn. Bhd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Supergenics Life Science Sdn. Bhd. \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Comac Medical","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHF6467","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Comac Medical","highestDevelopmentStatusID":"7","companyTruncated":"Chiesi Group \/ Comac Medical"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de N\u00eemes","sponsor":"Phaxiam Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Centre Hospitalier Universitaire de N\u00eemes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Centre Hospitalier Universitaire de N\u00eemes \/ Phaxiam Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Centre Hospitalier Universitaire de N\u00eemes \/ Phaxiam Therapeutics"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroBiologics \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            FibroBiologics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            FibroBiologics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CYWC628 (Fibroblast Spheroids) Safety & Efficacy In Refractory Diabetic Foot Ulcers vs SOC

                            Details : This drug candidate is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 31, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recce Pharmaceuticals Expands Phase I/II Trial of RECCE® 327 for Diabetic Foot Infections

                            Details : RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 27, 2024

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Supergenics Life Science Sdn. Bhd.

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Supergenics Life Science Sdn. Bhd.

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer

                            Details : Allogeneic Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 30, 2024

                            Lead Product(s) : Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recce Reports Positive Phase I/II Results of RECCE® 327 for Diabetic Infections

                            Details : RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 23, 2024

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE 327 for Diabetic Foot Infections

                            Details : RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for Diabetic Foot Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 24, 2023

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Murdoch Children’s Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children™s Research Institute

                            Details : The company’s work with Murdoch Children's has already played a pivotal role in the delivery of results surrounding ongoing pre-clinical programs, generating R327 (RECCE 327) data demonstrating strong bactericidal activity against a range of deadly pat...

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            December 19, 2022

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Murdoch Children’s Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients wit...

                            Details : RECCE® 327 (R327) is one of the first new classes of antibiotics in over 30 years with a universal mechanism of action that allow its compounds to continuously kill bacteria and multi-drug resistant superbugs.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 12, 2022

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aurealis Therapeutics

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed

                            Aurealis Therapeutics

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUP-16

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Xbiome

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Dia...

                            Details : Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 28, 2022

                            Lead Product(s) : AUP-16

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Xbiome

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Technophage

                            Portugal arrow
                            OTS 2025
                            Not Confirmed

                            Technophage

                            Portugal arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-102

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers

                            Details : TP-102 is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 18, 2021

                            Lead Product(s) : TP-102

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SaNOtize

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            SaNOtize

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers

                            Details : Nitric Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 16, 2021

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth